CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J

The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.Dublin, Sept. 30, 2026